Moomoo AI 已提取核心信息
Merck & Co., Inc., a leading pharmaceutical company, reported its financial results for the fourth quarter and full year of 2023 on February 1, 2024. The company announced a 6% increase in fourth-quarter worldwide sales to $14.6 billion compared to the same period in 2022, with full-year sales rising 1% to $60.1 billion. The growth was attributed to strong performance in oncology and vaccines, particularly KEYTRUDA and GARDASIL/GARDASIL 9. However, the company experienced a GAAP loss per share of $0.48 for the quarter, including a charge of $1.69 per share for a collaboration with Daiichi Sankyo. Non-GAAP EPS was $0.03. Full-year GAAP EPS was $0.14, and non-GAAP EPS was $1.51, both including significant charges related to business development transactions. Merck also announced the approval of a new restructuring program aimed at optimizing its manufacturing network, with expected completion by the end of 2031 and estimated costs of approximately $4.0 billion. The company's financial outlook for 2024 anticipates worldwide sales between $62.7 billion and $64.2 billion, with non-GAAP EPS expected to be between $8.44 and $8.59.
Merck & Co., Inc., a leading pharmaceutical company, reported its financial results for the fourth quarter and full year of 2023 on February 1, 2024. The company announced a 6% increase in fourth-quarter worldwide sales to $14.6 billion compared to the same period in 2022, with full-year sales rising 1% to $60.1 billion. The growth was attributed to strong performance in oncology and vaccines, particularly KEYTRUDA and GARDASIL/GARDASIL 9. However, the company experienced a GAAP loss per share of $0.48 for the quarter, including a charge of $1.69 per share for a collaboration with Daiichi Sankyo. Non-GAAP EPS was $0.03. Full-year GAAP EPS was $0.14, and non-GAAP EPS was $1.51, both including significant charges related to business development transactions. Merck also announced the approval of a new restructuring program aimed at optimizing its manufacturing network, with expected completion by the end of 2031 and estimated costs of approximately $4.0 billion. The company's financial outlook for 2024 anticipates worldwide sales between $62.7 billion and $64.2 billion, with non-GAAP EPS expected to be between $8.44 and $8.59.
领先的制药公司默沙东公司于2024年2月1日公布了其2023年第四季度和全年财务业绩。该公司宣布，与2022年同期相比，第四季度全球销售额增长6％，达到146亿美元，全年销售额增长1％，达到601亿美元。增长归因于肿瘤学和疫苗领域的强劲表现，尤其是KEYTRUDA和GARDASIL/GARDASIL 9。但是，该公司本季度的GAAP每股亏损为0.48美元，其中包括与第一三共合作的每股1.69美元的费用。非公认会计准则每股收益为0.03美元。全年公认会计准则每股收益为0.14美元，非公认会计准则每股收益为1.51美元，均包括与业务发展交易相关的重大费用。默沙东还宣布批准一项旨在优化其制造网络的新重组计划，预计将于2031年底完成，预计成本约为40亿美元。该公司2024年的财务展望预计全球销售额在627亿美元至642亿美元之间，非公认会计准则每股收益预计在8.44美元至8.59美元之间。
领先的制药公司默沙东公司于2024年2月1日公布了其2023年第四季度和全年财务业绩。该公司宣布，与2022年同期相比，第四季度全球销售额增长6％，达到146亿美元，全年销售额增长1％，达到601亿美元。增长归因于肿瘤学和疫苗领域的强劲表现，尤其是KEYTRUDA和GARDASIL/GARDASIL 9。但是，该公司本季度的GAAP每股亏损为0.48美元，其中包括与第一三共合作的每股1.69美元的费用。非公认会计准则每股收益为0.03美元。全年公认会计准则每股收益为0.14美元，非公认会计准则每股收益为1.51美元，均包括与业务发展交易相关的重大费用。默沙东还宣布批准一项旨在优化其制造网络的新重组计划，预计将于2031年底完成，预计成本约为40亿美元。该公司2024年的财务展望预计全球销售额在627亿美元至642亿美元之间，非公认会计准则每股收益预计在8.44美元至8.59美元之间。
有用
没用